Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT07491094

Repeated Examinations for Typing Pulmonary Embolism

Conditions: Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute, Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism With Right Ventricle Enlargement, Pulmonary Embolism (PE)

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 400
Sponsor: Sahlgrenska University Hospital

Location: Sahlgrenska University Hospital/Mölndal Gothenburg Region Västra Götaland

Summary

PURPOSE The two related purposes of the RE-TyPE study are: 1. To improve understanding of the early clinical course of intermediate-high risk pulmonary embolism and its association with outcome and 2. To establish a platform for longitudinal follow-up for all pulmonary embolism at Sahlgrenska University Hospital HYPOTHESES 1. The dynamic pattern of change, evaluated thorough repeated measures of biomarkers, electrocardiography and echocardiography during the first 48 hours after pulmonary embolism, better predicts outcome than static measurements currently used to predict outcome 2. Establishment of a platform for longitudinal follow-up will improve quality of care and outcome for patients with pulmonary embolism at Sahlgrenska University Hospital

Eligibility Criteria

Inclusion Criteria: 1. Adult patients (≥ 18 years old) who is diagnosed with, or followed as out-patients for, PE at Sahlgrenska University Hospital 2. Written informed consent Exclusion Criteria from Cohort A: 1. Low risk, intermediate-low risk or high risk PE\* 2. \>48 hours since PE diagnosis 3. Expected inability to comply with the protocol (e.g. dementia) Exclusion Criterium from Cohort B: 1\. Not geographically belonging to Sahlgrenska University Hospital \*If biomarkers (and/or echocardiography) are not available in hemodynamically stable patients, RV/LV-ratio \>1 will be considered as preliminary intermediate-high risk. If biomarkers later fall out negative, the patient will be considered as intermediate-low risk and will be moved to Cohort B

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07491094). StuddyBuddy aggregates publicly available trial information.